Mostrando 9 resultados de: 9
Filtros aplicados
Publisher
Clinical Pharmacology and Therapeutics(1)
European Journal of Clinical Pharmacology(1)
European Journal of Drug Metabolism and Pharmacokinetics(1)
Journal of Neurology Neurosurgery and Psychiatry(1)
Molecular Biology Reports(1)
Acetylator polymorphism in Parkinson's disease
ArticleAbstract: Acetylator phenotype has been determined using sulphamethazine in 100 patients with Parkinson's disePalabras claves:acetylator phenotype, debrisoquine oxidation, drug polymorphism, Parkinsonism, sulphamethazineAutores:Adrián LLerena, Benitez Rodriguez J., Cobaleda J., Fernandez-Gundin M.J., Jimenez F.J., Ladero J.M., Martinez C., Muñoz J.J.Fuentes:scopusGenomic Ancestry, CYP2D6, CYP2C9, and CYP2C19 Among Latin Americans
ArticleAbstract: We present the distribution of CYP2D6, CYP2C9, and CYP2C19 variants and pbkp_redicted phenotypes inPalabras claves:Autores:Adrián LLerena, Alvárez M., Barrantes R., Borbón-Orejuela A., Calzadilla L.R., Céspedes-Garro C., Cobaleda J., de Andrés F., Delgado R., Dorado P., Enrique Terán, Estévez-Carrizo F.E., Ferreiro V., Francisco J.López Hernández, Fricke-Galindo I., Galaviz-Hernandez C., Garza-Ocañas L., Gilman R.H., Grazina M., Humberto Fariñas, Jiménez-Arce G., Jung-Cook H., Lares-Aseff I., Lazalde-Ramos B.P., López-López M., Michelin L.A., Monroy-Jaramillo N., Moya G.E., Naranjo M.E.G., Ortega-Vázquez A., Ortiz-López R., Penãs-Lledó E.M., Pérez B., Pérez-Páramo Y.X., Ramírez-Roa R., Remírez D., Rodeiro I., Rodrigues-Soares F., Rojas-Martinez A., Santiago Terán, Sarmiento A.P., Scliar M.O., Sosa-Macías M.G., Tarazona-Santos E.M., Tinoco C.A., Zamudio R.Fuentes:googlescopusHigh frequency of CYP2D6 ultrarapid metabolizers in Spain: Controversy about their misclassification in worldwide population studies
ArticleAbstract: A high frequency (7-10%) of CYP2D6 ultrarapid metabolizers estimated from the genotype (gUMs) has bePalabras claves:Autores:Adrián LLerena, Cobaleda J., de Andrés F., Delgado A., Naranjo M.E.G., Penãs-Lledó E.M.Fuentes:scopusOxidative polymorphism of debrisoquine in Parkinson's disease
ArticleAbstract: Oxidative phenotype and metabolic ratio (MR) of debrisoquine (DBQ) have been determined in 87 patienPalabras claves:Autores:Adrián LLerena, Benitez Rodriguez J., Cobaleda J., Jimenez-Jimenez F.J., Ladero J.M., Martínez C., Muñoz J.J., Puerto A.M., Valdivielso M.J.Fuentes:scopusInterethnic differences in UGT1A4 genetic polymorphisms between Mexican Mestizo and Spanish populations
ArticleAbstract: UDP-glucuronosyltransferase 1A4 (UGT1A4) is a phase II drug-metabolizing enzyme that catalyzes the gPalabras claves:Glucuronidation, Interethnic differences, Mexican-Mestizo, Spaniards, UGT1A4Autores:Adrián LLerena, Alonso M.E., Cobaleda J., Dorado P., Gallego-Aguilera A., López M.L., MELANIE BRIGETTE ARROYO LOPEZ, Monroy-Jaramillo N., Ortega A., Penãs-Lledó E.M., Silva-Zolezzi I.Fuentes:googlescopusInterethnic differences in drug metabolism: Influence of genetic and environmental factors on debrisoquine hydroxylation phenotype
Conference ObjectAbstract: Genetic and environmental factors are determinants of the interindividual and interethnic variabilitPalabras claves:CYP2D6, debrisoquine, gender, pharmacogenetics, smokingAutores:Adrián LLerena, Benitez Rodriguez J., Cobaleda J., Martínez C.Fuentes:scopusInterethnic variability in CYP2D6, CYP2C9, and CYP2C19 genes and pbkp_redicted drug metabolism phenotypes among 6060 ibero-and native Americans: RIBEF-CEIBA consortium report on population pharmacogenomics
ArticleAbstract: Pharmacogenetic variation in Latin Americans is understudied, which sets a barrier for the goal of gPalabras claves:Amerindians, CYP2C19, CYP2C9, CYP2D6, drug metabolism, LATIN AMERICANS, pharmacogenetics, Precision MedicineAutores:Adrián LLerena, Alvárez M., Barrantes R., Borbón-Orejuela A., Calzadilla L.R., Céspedes-Garro C., Cobaleda J., de Andrés F., Delgado R., Dorado P., Enrique Terán, Estévez-Carrizo F.E., Fcrreiro V., Francisco J.López Hernández, Fricke-Galindo I., Galaviz-Hernandez C., Garza-Ocañas L., Gilman R.H., Gouveia M.H., Grazina M., Humberto Fariñas, Jiménez-Arce G., Jung-Cook H., Lares-Aseff I., Lazalde-Ramos B.P., López-López M., Monroy-Jaramillo N., Moya G.E., Naranjo M.E.G., Ortega-Vázquez A., Ortiz-López R., Penãs-Lledó E.M., Pérez B., Pérez-Páramo Y.X., Ramírez-Roa R., Remírez D., Rodeiro I., Rodrigues-Soares F., Rojas-Martinez A., Santiago Terán, Sarmiento A.P., Scliar M.O., Sosa-Macías M.G., Tarazona-Santos E.M., Tinoco C.A., Zamudio R.Fuentes:googlescopusVEGF-related polymorphisms identified by GWAS and risk for major depression
ArticleAbstract: Depression is a common, severe, disabling mental disease that affects millions of people of all agesPalabras claves:Autores:Adrián LLerena, Cobaleda J., de Andrés F., Delgado A., Lamont J., Martin M., Murray H., Penãs-Lledó E.M., Siest G., Stathopoulou M.G., Visvikis-Siest S., Xie T.Fuentes:scopusRelevance of the ancestry for the variability of the Drug-Metabolizing Enzymes CYP2C9, CYP2C19 and CYP2D6 polymorphisms in a multiethnic Costa Rican population
ArticleAbstract: CYP2C9, CYP2C19 and CYP2D6 metabolize around 40 % of drugs and their genes vary across populations.Palabras claves:Afro-Caribbean, Amerindian, COSTA RICA, CYP2C19, CYP2C9, CYP2D6, Genomic ancestryAutores:Adrián LLerena, Alonso-Vilatela E., Alvárez M., Barrantes R., Borbón-Orejuela A., Calzadilla L.R., Céspedes-Garro C., Cobaleda J., de Andrés F., Delgado R., Dorado P., Enrique Terán, Estévez-Carrizo F.E., Ferreiro V., Francisco J.López Hernández, Fricke-Galindo I., Galaviz-Hernandez C., Garza-Ocañas L., Grazina M., Humberto Fariñas, Jiménez-Arce G., Jung-Cook H., Lares-Aseff I., Lazalde-Ramos B.P., López-López M., Monroy-Jaramillo N., Naranjo M.E.G., Ortega-Vázquez A., Ortiz-López R., Penãs-Lledó E.M., Pérez B., Pérez-Páramo Y.X., Ramírez-Roa R., Remírez D., Rodeiro I., Rodrigues-Soares F., Rojas-Martinez A., Santiago Terán, Sarmiento A.P., Sosa-Macías M.G., Tarazona-Santos E.M., Tinoco C.A., Vázquez T.C.Fuentes:scopus